T.P. MAKAROVA^1, 2, M.A. PETROVA^1, 2, YU.S. MELNIKOVA¹, M.R. SHAIDULLINA^1, 2

 ¹Kazan State Medical University, Kazan

²Children’s Republican Clinical Hospital, Kazan

 Contact details:

Makarova T.P.  — Dr. Sci. (Medicine), Professor of the Department of Hospital Pediatrics

Address: 49 Butlerov Str., 420012 Kazan, tel.: +7-903-313-82-98, e-mail: makarova-kgmu@mail.ru

 Diabetes mellitus (DM) is a disease accompanied by various complications, one of which is diabetic nephropathy (DN).

The purpose — to study early markers of renal damage in children and adolescents with type I diabetes mellitus (DM1).

Material and methods. The study included 87 children with DM1; the control group consisted of 21 conditionally healthy children. All patients with DM1 were divided into two groups depending on the presence (n = 37) or absence of signs of kidney damage (n = 50). Special research methods included measuring NGAL and L-FABP1 concentration in urine with enzyme immunoassay (EIA).

Results. We revealed a statistically significant increase in the level of NGAL and L-FABP markers in urine in type 1 diabetes mellitus in children compared to the control group. NGAL has direct correlations with the presence of protein in the urine and microalbuminuria, and inverse correlation with CKF. The level of L-FABP was statistically significantly higher in children with DM1 regardless of the presence or absence of kidney damage and gradually increased with increasing age of the disease. A prognostic model was developed to determine the probability of kidney damage in children with DM1 depending on the NGAL concentration in urine.

Conclusions. NGAL levels were more than 3 times higher in the group of children with DM1 with kidney damage both compared to the control group and to the group of children with DM1 without kidney damage (p = 0.029). L-FABP was higher in the main group compared to the control group regardless of the presence or absence of kidney damage (p = 0.001). Elevated values of NGAL and L-FABP levels in urine have diagnostic significance in the formation of CKD in children with DM1. Using the prognostic model, the threshold value of NGAL (> 2ng/mL) was revealed, at which there is a high risk of kidney damage in children with DM1.

Key words: diabetic nephropathy, type 1 diabetes mellitus, children, NGAL, L-FABP.

REFERENCES

1. Baroud S., Mirza L. New-onset type 1 diabetes mellitus after treatment with nivolumab for melanoma. Cureus, 2021, vol. 13 (10), p. e18679. DOI: 10.7759/cureus.18679
2. IDF Diabetes Atlas, 9th edition. Brussels: International Diabetes Federation, 2019, available from: https://www.diabetesatlas.org/en/
3. Dedov I.I., Shestakova M.V., Vikulova O.K. et al. Atlas of the Diabetes Registry of the Russian Federation. Status 2018. Sakharnyy diabet, 2019, no. 22 (2S), pp. 4–61 (in Russ.). DOI: 10.14341/DM12208
4. Dedov I.I., Shestakova M.V., Vikulova O.K., Zheleznyakova A.V., Isakov M.A. Epidemiological characteristics of diabetes mellitus in the Russian Federation: clinical and statistical analysis based on the Federal Diabetes Registry as of 01.01.2021. Sakharnyy diabet, 2023, vol. 24, no. 3, pp. 204–221. DOI: 10.14341/DM12759
5. Modarelli R., Sarah S., Ramaker M.E., Bolobiongo M., Benjamin R., Gumus Balikcioglu P. Pediatric diabetes on the rise: trends in incident diabetes during the COVID-19 pandemic. J. Endocr. Soc, 2022, vol. 6 (4). bvac024. DOI: 10.1210/jendso/bvac024
6. Popykhova E.B., Stepanova T.V., Lagutina D.D., Kiriyazi T.S., Ivanov A.N. The role of diabetes mellitus in the occurrence and development of endothelial dysfunction. Problemy endokrinologii, 2020, no. 66 (1), pp. 47–55 (in Russ.). DOI: 10.14341/probl12212
7. Tolstikova E.A. Diabetic nephropathy in children. Z turbotoyu pro ditinu, 2018, no. 1 (63), pp. 12–17 (in Russ.).
8. Shutskaya Zh.V. Diabetic nephropathy in children and adolescents: features of diagnosis and treatment. Pediatriya im. G.N. Speranskogo, 2009, no. 87 (3), pp. 100–104 (in Russ.).
9. Caramori M.L., Fioretto P., Mauer M. Low glomerular filtration rate in normoalbuminuric type 1 diabetic patients: an indicator of more advanced glomerular lesions. Diabetes, 2003, vol. 52, pp. 1036–1040.
10. Wang K., Hu J., Luo T., Wang Y., Yang S., Qing H. et al. Effects of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on all-cause mortality and renal outcomes in patients with diabetes and albuminuria: a systematic review and meta-analysis. Kidney Blood Press Res, 2018, vol. 43 (3), pp. 768–779. DOI: 10.1159/000489913
11. MacIsaac RJ, Ekinci EI, Jerums G. Progressive diabetic nephropathy. How useful is microalbuminuria? Kidney Int, 2014, vol. 86 (1), pp. 50–57. DOI: 10.1038/ki.2014.98
12. Coca S.G., Nadkarni G.N., Huang Y., Moledina D.G., Rao V., Zhang J. et al. Plasma biomarkers and kidney function decline in early and established diabetic kidney disease. J. Am. Soc. Nephrol, 2017, vol. 28 (9), pp. 2786–2793. DOI: 10.1681/ASN.2016101101
13. Marakala V. Neutrophil gelatinase-associated lipocalin (NGAL) in kidney injury — A systematic review. Clin. Chim. Acta, 2022, vol. 536, pp. 135–141. DOI: 10.1016/j.cca.2022.08.029
14. Vyalkova A.A., Zorin I.V., Sedashkina O.A., Kopylov Yu.N., Belova M.A., Gaykova L.A. et al. Biomarkers of renal damage in congenital malformations of the urinary system in children. Nefrologiya, 2012, no. 16 (3/2), pp. 68–75 (in Russ.).
15. Popykhova Era Borisovna, Ivanov A.N., Stepanova T.V., Lagutina D.D., Savkina A.A. Diabetic nephropathy: possibilities of early laboratory diagnostics and prognosis of the course (literature review). Klinicheskaya laboratornaya diagnostika, 2021, vol. 66, no. 10, pp. 593–602 (in Russ.).
16. Batte A., Menon S., Ssenkusu J.M., Kiguli S., Kalyesubula R., Lubega J. et al. Neutrophil gelatinase-associated lipocalin is elevated in children with acute kidney injury and sickle cell anemia, and predicts mortality. Kidney Int, 2022, vol. 102 (4), pp. 885–893. DOI: 10.1016/j.kint.2022.05.020
17. Abbas Q., Laghari P., Jurair H., Nafis J., Saeed B., Qazi M.F. et al. Neutrophil gelatinase-associated lipocalin as a predictor of acute kidney injury in children with shock: a prospective study. Cureus, 2023, vol. 15 (1), e34407. DOI: 10.7759/cureus.34407
18. Xu Y., Xie Y., Shao X., Ni Z., Mou S. L-FABP: A novel biomarker of kidney disease. Clin. Chim. Acta, 2015, vol. 445, pp. 85–90. DOI: 10.1016/j.cca.2015.03.017
19. Kuz’min O.B., Zhezha V.V., Belyanin V.V., Buchneva N.V., Landar’ L.N., Serdyuk S.V. Diagnostic and prognostic value of renal tubular damage biomarkers ngal, kim-1, l-fabp in patients with chronic kidney disease. Nefrologiya, 2017, vol. 21 (2), pp. 24–32 (in Russ.).
20. Plenkina Lidiya Vladimirovna, Simonova O.V., Popova S.V., Rozinova V.A. The role of fatty acid binding proteins in assessing kidney damage in patients with ankylosing spondylitis. Nauchno-prakticheskaya revmatologiya, 2020, vol. 58 (1), pp. 22–25 (in Russ.).
21. Bobkova I.N., Shestakova M.V., Shchukina A.A. Diabetic nephropathy — focus on podocyte damage. Nefrologiya, 2015, vol. 19 (2), pp. 33–44 (in Russ.).
22. Kutsenko L.V., Vyalkova A.A., Savel’eva E.V., Chesnokova S.A., Meshcheryakova A.I. Urinary lipocalin is a predictor of secondary nephropathies in endocrine diseases in children. Rossiyskiy pediatricheskiy zhurnal, 2022, vol. 3 (1), p. 168 (in Russ.).
23. Nikolaev A.O., Nastausheva T.L., Chichuga E.M., Gurovich O.V., Kondrat’eva I.V., Volosovets G.G. Urinary markers of kidney damage KIM-1, NGAL and IL-18 in children with type 1 diabetes mellitus. Rossiyskiy pediatricheskiy zhurnal, 2022, vol. 3 (1), p. 219 (in Russ.).
24. Papadopoulou-Marketou N., Margeli A., Papassotiriou I., Chrousos G.P., Kanaka-Gantenbein C., Wahlberg J. NGAL as an Early predictive marker of diabetic nephropathy in children and young adults with type 1 diabetes mellitus. J. Diabetes Res, 2017, vol. 2017. 7526919. DOI: 10.1155/2017/7526919
25. Ugarte F., Santapau D., Gallardo V., Garfias C., Yizmeyián A., Villanueva S. et al. Urinary extracellular vesicles as a source of ngal for diabetic kidney disease evaluation in children and adolescents with type 1 diabetes mellitus. Front. Endocrinol, 2022, vol. 12. 654269. DOI: 10.3389/fendo.2021.654269
26. Latifova N., Shakhverdieva I., Vagabova G., Gulieva S., Alieva D. Evaluation of serum levels of L-FABP and cathelikidin as diagnostic markers in various kidney pathologies exacerbated by diabetes. Azerbaijan Med. J, 2023, no. 3, pp. 71–74 (in Russ.).
27. Zhang L., Xue S., Wu M., Dong D. Performance of urinary liver-type fatty acid-binding protein in diabetic nephropathy: A meta-analysis. Front. Med, 2022, vol. 9. 914587. DOI: 10.3389/fmed.2022.914587